View in EDS HTML Full Text PDF Full Text

Selective blockade of latent TGF-β1 activation suppresses tissue fibrosis with good safety.

Saved in:
Bibliographic Details
Title: Selective blockade of latent TGF-β1 activation suppresses tissue fibrosis with good safety.
Authors: Kanamori M; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan., Sato I; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan., Koo CX; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.; Health Sciences Authority, Singapore, Singapore., Sun Y; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore., Kawauchi H; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan., Nakagawa K; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan., Murai A; Translational Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan., Asanuma K; Translational Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan., Gan SW; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore., Pang CL; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.; AbbVie Operations Singapore Pte. Ltd., Singapore, Singapore., Shimizu Y; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan., Shida-Kawazoe M; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan., Kanamaru C; Translational Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan., Kayukawa Y; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan., Hada N; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan., Ohmine K; Translational Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan., Kitazawa T; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan., Nezu J; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.; Mochida Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Igawa T; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan., Shimada H; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan. shimada.hideaki12@chugai-pharm.co.jp.; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore. shimada.hideaki12@chugai-pharm.co.jp.
Source: Communications medicine [Commun Med (Lond)] 2026 Jan 28; Vol. 6 (1). Date of Electronic Publication: 2026 Jan 28.
Publication Type: Journal Article
Journal Info: Publisher: Nature Portfolio Country of Publication: England NLM ID: 9918250414506676 Publication Model: Electronic Cited Medium: Internet ISSN: 2730-664X (Electronic) Linking ISSN: 2730664X NLM ISO Abbreviation: Commun Med (Lond) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41606188
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Selective blockade of latent TGF-β1 activation suppresses tissue fibrosis with good safety.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kanamori+M%22">Kanamori M</searchLink>; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Sato+I%22">Sato I</searchLink>; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Koo+CX%22">Koo CX</searchLink>; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.; Health Sciences Authority, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Sun+Y%22">Sun Y</searchLink>; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Kawauchi+H%22">Kawauchi H</searchLink>; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Nakagawa+K%22">Nakagawa K</searchLink>; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Murai+A%22">Murai A</searchLink>; Translational Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Asanuma+K%22">Asanuma K</searchLink>; Translational Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Gan+SW%22">Gan SW</searchLink>; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Pang+CL%22">Pang CL</searchLink>; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore.; AbbVie Operations Singapore Pte. Ltd., Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Shimizu+Y%22">Shimizu Y</searchLink>; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Shida-Kawazoe+M%22">Shida-Kawazoe M</searchLink>; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Kanamaru+C%22">Kanamaru C</searchLink>; Translational Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Kayukawa+Y%22">Kayukawa Y</searchLink>; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Hada+N%22">Hada N</searchLink>; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Ohmine+K%22">Ohmine K</searchLink>; Translational Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Kitazawa+T%22">Kitazawa T</searchLink>; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Nezu+J%22">Nezu J</searchLink>; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.; Mochida Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Igawa+T%22">Igawa T</searchLink>; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Shimada+H%22">Shimada H</searchLink>; Research Division, Chugai Pharmaceutical Co. Ltd., Yokohama, Kanagawa, Japan. shimada.hideaki12@chugai-pharm.co.jp.; Chugai Pharmabody Research Pte. Ltd., Singapore, Singapore. shimada.hideaki12@chugai-pharm.co.jp.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229918250414506676%22">Communications medicine</searchLink> [Commun Med (Lond)] 2026 Jan 28; Vol. 6 (1). <i>Date of Electronic Publication: </i>2026 Jan 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Portfolio%22">Nature Portfolio </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9918250414506676 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2730-664X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222730664X%22">2730664X </searchLink><i>NLM ISO Abbreviation: </i>Commun Med (Lond) <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41606188
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s43856-026-01408-w
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Selective blockade of latent TGF-β1 activation suppresses tissue fibrosis with good safety.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kanamori M
      – PersonEntity:
          Name:
            NameFull: Sato I
      – PersonEntity:
          Name:
            NameFull: Koo CX
      – PersonEntity:
          Name:
            NameFull: Sun Y
      – PersonEntity:
          Name:
            NameFull: Kawauchi H
      – PersonEntity:
          Name:
            NameFull: Nakagawa K
      – PersonEntity:
          Name:
            NameFull: Murai A
      – PersonEntity:
          Name:
            NameFull: Asanuma K
      – PersonEntity:
          Name:
            NameFull: Gan SW
      – PersonEntity:
          Name:
            NameFull: Pang CL
      – PersonEntity:
          Name:
            NameFull: Shimizu Y
      – PersonEntity:
          Name:
            NameFull: Shida-Kawazoe M
      – PersonEntity:
          Name:
            NameFull: Kanamaru C
      – PersonEntity:
          Name:
            NameFull: Kayukawa Y
      – PersonEntity:
          Name:
            NameFull: Hada N
      – PersonEntity:
          Name:
            NameFull: Ohmine K
      – PersonEntity:
          Name:
            NameFull: Kitazawa T
      – PersonEntity:
          Name:
            NameFull: Nezu J
      – PersonEntity:
          Name:
            NameFull: Igawa T
      – PersonEntity:
          Name:
            NameFull: Shimada H
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 01
              Text: 2026 Jan 28
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2730-664X
          Numbering:
            – Type: volume
              Value: 6
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Communications medicine
              Type: main
ResultId 1